Joint on chip technology: a new era in studying rheumatic disorders
Osteoarthritis is the most common degenerative joint disease which cannot be effectively treated. Consequently there is a large unmet need for disease modifying treatments. Thus far many attempts failed at phase 2 and 3 clinical trials due to lack of efficacy. This is in part due to the lack of translational power of frequently used animal models. To address this issue we have engineered the first prototypes of a cartilage-on-chip and a synovial membrane-on-chip which can be combined in a multi-organ on-chip device; the Joint-on-Chip (JoC). In my presentation I will discuss the current state of the art and will show first data how we use these new models for developing dearly needed disease modifying treatments.
Personal information
Organisation | University of Twente |
Position | Professor |
Biography
Marcel Karperien studied biology at Utrecht University. He joined the University of Twente in 2007 where he established the Department of Developmental BioEngineering. His work is focused on developing technology inspired solutions for the treatment of osteoarthritis. Current research interests include injectable hydrogels for intra-articular application in the diseased joint, the development of technology for the early diagnosis of osteoarthritis and the engineering of joint on chips.
Programme
Time | Session | Location | |
|---|---|---|---|
13.15 - 14.30 | Organ on a chip: Better designs, better health | Innovation Stage | Ground floor |